← Back to Search

Control for Heart Attack (SSCORE Trial)

N/A
Recruiting
Led By William W O'Neill, MD
Research Sponsored by TherOx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

The SuperSaturated Oxygen Comprehensive Observational Registry (SSCORE) registry, a prospectively designed observational study, aims to evaluate the clinical utility and effectiveness of SuperSaturated Oxygen (SSO2) Therapy versus percutaneous coronary intervention (PCI) alone among patients with anterior acute myocardial infarction (AMI) in routine clinical practice. The goal is to collect real-world data from patients treated with SSO2 Therapy to determine its impact on the overall heart failure (HF) burden on patients and healthcare systems compared with usual care for treatment of patients with AMI. The SSCORE Registry will generate effectiveness and healthcare resource utilization data that will be used in cost-effectiveness analysis modeling.

Eligible Conditions
  • Acute Myocardial Infarction
  • Heart Attack

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cardiovascular (CV) death or Heart Failure (HF) burden at 1 year
Secondary study objectives
Change in % of Left ventricular ejection fraction (LVEF)
Change in EQ5D-3L Score
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ-23) Score
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: SuperSaturated Oxygen (SSO2) TherapyExperimental Treatment1 Intervention
Treated with SSO2
Group II: ControlExperimental Treatment1 Intervention
Not treated with SSO2

Find a Location

Who is running the clinical trial?

TherOxLead Sponsor
5 Previous Clinical Trials
857 Total Patients Enrolled
William W O'Neill, MDPrincipal InvestigatorHenry Ford Hospital
William W O'Neill, MDPrincipal InvestigatorHenry Ford Hospital
3 Previous Clinical Trials
1,150 Total Patients Enrolled
~667 spots leftby Mar 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top